The causes, consequences, and treatment of left or right heart failure

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 237-254

  Pazos López, Pablo ^a   Peteiro Vázquez, Jesús ^a   Carcía Campos, Ana ^a   García Bueno, Lourdes ^a   de Torres, Juan Pablo Abugattas ^a   Castro Beiras, Alfonso ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Cause; Consequence; Heart failure; Treatment

Indexed keywords

HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; PHYSIOLOGY; REVIEW;

HEART FAILURE; HOSPITALIZATION; HUMANS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 80053310445     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S10669     Document Type: Review

References (135)

1. Hunt SA, Abraham WT, Chin MS, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am CollCardiol. 2009;53(15):e1-e90.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388-2442.
3. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355(3):260-269.
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3): 251-259.
5. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-1146.
6. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001; 22(3):228-236.
7. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998; 97(3):282-289.
8. Repetto A, Dal Bello B, Pasotti M, et al. Coronary atherosclerosis in end stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J. 2005;26(15):1519-1527.
9. Hedrich O, Jacob M, Hauptman PJ. Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coron Artery Dis. 2004;15(5):291-297.
10. Shizukuda Y, Sonnenblick EH, Le Jemtel TH, Forman R. Coronary flow reserve of nonischemic heart failure. Congest Heart Fail. 1999; 5(5):208-215.
11. Santagata P, Rigo F, Gherardi S, et al. Clinical and functional determinants of coronary flow reserve in non-ischemic dilated cardiomyopathy: an echocardiographic study. Int J Cardiol. 2005;105(1):46-52.
12. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25):2981-2988.
13. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol. 1996;19(1):95-106.
14. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339(3):173-181.
15. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161(7):996-1002.
16. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 1996; 156(16):1789-1796.
17. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996; 275(20):1557-1562.
18. Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J. 2000;21(20):1653-1665.
19. Weber KT, Sun Y, Guarda E. Structural remodelling in hypertensive heart disease and the roles of hormones. Hypertension. 1994; 23(6 Pt 2):869-877.
20. Inouye I, Massie B, Loge, et al. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol. 1984;53(1):120-126.
21. Smith VE, Schulman P, Karimeddini MK, White WB, Meeran MK, Katz AM. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy. J Am CollCardiol. 1985;5(4):869-874.
22. Pearson AC, Gudipati C, Nagelhout D, Sear J, Cohen JD, Labovitz AJ. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am CollCardiol. 1991;17(2):422-430.
23. Devereux RB. Left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance. J Am CollCardiol. 1989; 13(2):337-339.
24. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation. 1987; 75(1 Pt 2):I19-I25.
25. González A, Fortuño MA, Querejeta R, et al. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res. 2003; 59(3):549-562.
26. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-276.
27. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am CollCardiol. 2005;45(7):969-981.
28. Mestroni L, Maisch B, McKenna, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999;20(2):93-102.
29. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004; 363(9424):1881-1891.
30. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-225.
31. Fagard R. Athlete's heart. Heart. 2003;89(12):1455-1461.
32. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373(9671):1289-1300.
33. Engberding R, Yelbuz TM, Breithardt G. Isolated noncompaction of the left ventricular myocardium-a review of the literature two decades after the initial case description. Clin Res Cardiol. 2007;96(7):481-488.
34. Murphy RT, Thaman R, Blanes JG, et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J. 2005;26(2):187-192. Erratum in: Eur Heart J. 2008;29(15):1925.
35. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47(1):33-39.
36. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation. 1992;85(6):2119-2131.
37. Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am CollCardiol. 1995;25(6):1239-1249.
38. Rostagno C, Gensini GF. Six minute walk test: a simple and useful test to evaluate functional capacity in patients with heart failure. Intern Emerg Med. 2008;3(3):205-212.
39. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-1487.
40. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW; ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007; 153(6):1021-1028.
41. Brown DW, Haldeman GA, Croft JB, Giles WH, Mensah GA. Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. Am Heart J. 2005;150(3):448-454.
42. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am CollCardiol. 2004;43(8):1432-1438.
43. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137(2):352-360.
44. Mosterd A, Reitsma JB, Grobbee DE. ACE inhibition and hospitalisation rates for heart failure in the Netherlands 1980-1999. The end of an epidemic? Heart. 2002;87(1):388-392.
45. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004; 25(18):1614-1619.
46. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347(18):1397-1402.
47. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000; 83(5):505-510.
48. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98(21):2282-2289.
49. Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002; 23(23):1861-1866.
50. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart. 2003; 89(6):615-620.
51. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001; 134(7): 550-560.
52. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292(3):344-350.
53. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424-1433.
54. Deedwania PC. The key to unraveling the mystery of mortality in heart failure: an integrated approach. Circulation. 2003;107(13): 1719-1721.
55. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetinalfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117(4):526-535.
56. Szucs TD, Sokolovic E. Economic significance of heart failure. An overview of costs and economics of therapy. Herz. 2000;25(5):538-546.
57. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4(3):361-371.
58. Mohammadi M, Ekman I, Schaufelberger M. Relationship between blood pressure levels and adherence to medication in patients with chronic heart failure: how come? Vasc Health Risk Manag. 2009;5(1):13-19.
59. Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure. Health Aff (Millwood). 2009;28(1):179-189.
60. Ciccone MM, Aquilino A, Cortese F, et al. Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo). Vasc Health Risk Manag. 2010;6:297-305.
61. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;8:CD007228.
62. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363(24):2301-2309.
63. Koehler F, Winkler S, Schieber M, et al. Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail. 2010;12(12):1354-1362.
64. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-418.
65. Baibars M, Ibrahim A, Fang JC, Sipahi I. Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy. Future Cardiol. 2010;6(6):743-747.
66. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(5):433-443.
67. Smart N. Exercise training for heart failure patients with and without systolic dysfunction: an evidence-based analysis of how patients benefit. Cardiol Res Pract. 2010;2011. pii:837238.
68. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). Br Med J. 2004;328(7433):189.
69. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-1450.
70. Ramani GV, Uber PA, Mehra MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc. 2010;85(2):180-195.
71. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995; 57(6):601-609.
72. Herchuelz A, Derenne F, Deger F, et al. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance. J Pharmacol Exp Ther. 1989;248(3):1175-1181.
73. Risler T, Schwab A, Kramer B, Braun N, Erley C. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology. 1994;84(Suppl 2):155-161.
74. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am CollCardiol. 1996;28(2): 376-382.
75. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30(3):229-249.
76. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105(4):771-772.
77. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91(7):2043-2048.
78. Bastien NR, Juneau AV, Ouellette J, Lambert C. Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival. Cardiovasc Res. 1999;43(1):77-85.
79. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273(18):1450-1456. Erratum in: JAMA. 1995; 274(6):462.
80. Packer M, Medina N, Yushak M, Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation. 1983;68(4):803-812.
81. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987;106(3):346-354.
82. Israili ZH, Hall WD. Cough and angioneuroticedema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234-242.
83. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40(2):141-144.
84. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53-57.
85. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645.
86. Struthers AD. Angiotensin II receptor antagonists for heart failure. Heart. 1998;80(1):5-6.
87. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high risk acute myocardial infarction. Ann Intern Med. 2004;141(9):693-704. Erratum in: Ann Intern Med. 2005; 42(5):391.
88. Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract. 2008;62(9):1397-1402.
89. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
90. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
91. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295-1302.
92. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22): 1651-1658.
93. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199.
94. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3):215-225.
95. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J. 1998; 19(3):481-489.
96. Packer M, Poole-Wilson PA, Armstrong PW, et al; for the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312-2318.
97. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996; 2(1):47-54.
98. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101(6):594-597.
99. Pitt B, Zannad F, Remme WJ, et al; Randomized Spironolactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
100. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. Erratum in: N Engl J Med. 2003; 348(22):2271.
101. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. New Eng J Med. 2011; 364(1):11-21.
102. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of the Veterans Administration Cooperative Study. N Engl J Med. 1986; 314(24):1547-1552.
103. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbidedinitrate in the treatment of chronic heart failure. N Engl J Med. 1991;325(6):303-310.
104. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbidedinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057. Erratum in: N Engl J Med. 2005;352(12):1276.
105. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109(24):2959-2964.
106. Gheorghiade M, Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation. 1991;84(5):2181-2186.
107. The effect of digoxin on mortality and morbidity in patients with heart failure. Digitalis Investigation Group. N Engl J Med. 1997;336(8):525-533.
108. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am CollCardiol. 2002;39(7):1151-1158.
109. Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2007;134(6):1540-1547.
110. Di Salvo TG, Acker MA, Dec GW, Byrne JG. Mitral valve surgery in advanced heart failure. J Am CollCardiol. 2010;55(4):271-282.
111. Diodato MD, Moon MR, Pasque MK, et al. Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: a propensity analysis. Ann Thorac Surg. 2004;78(3):794-799.
112. Jones RH, Velazquez EJ, Michler RE, et al; STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705-1717.
113. Moss AJ, Zareba W, Hall WJ, et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883.
114. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardio-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237. Erratum in: N Engl J Med. 2005;352(20):2146.
115. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am CollCardiol. 2006;48(54):e247-e346.
116. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150.
117. Auricchio A, Kloss M, Trautmann SI, Rodner S, Klein H. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. Am J Cardiol. 2002;89(2):198-203.
118. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-1549.
119. McAlister FA, Eskowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297(22):2502-2514.
120. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357(24):2461-2471.
121. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008;117(20):2608-2616.
122. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-1338.
123. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am CollCardiol. 2008;52(23):1834-1843.
124. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am CollCardiol. 2009;54(20):1837-1846.
125. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010;31(21):2677-2687.
126. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.
127. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241-2251.
128. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twentyseventh official adult heart transplant report-2010. J Heart Lung Transplant. 2010;29(10):1089-1103.
129. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886-894.
130. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial. Lancet. 2003;362(9386):777-781.
131. Massie BM, Carson PE, McMurray JJ, et al; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med. 2008;359(23):2456-2467.
132. Ahmed A, Rich MW, Fleg JL, et al. Effect of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397-403.
133. Hernandez AF, Hammil BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. J Am CollCardiol. 2009;53(2): 184-192.
134. Skhiri M, Hunt SA, Denault AY, Haddad F. Evidence-based management of right heart failure: a systematic review of an empiric field. Rev Esp Cardiol. 2010;63(4):451-471.
135. Clark AL. Origin of symptoms in chronic heart failure. Heart. 2006; 92(1):12-16.